Zanzalintinib: colorectal-cancer FDA decision
Exelixis reconfirmed March 3, 2027 for FDA review of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer in its October 29 update. A September extension superseded December 3, 2026 after additional safety and efficacy data were submitted.
What matters
Follow the exact application, indication and requested label. An FDA decision concerns the drug program, while the company’s stock also reflects its other assets and business.
- December 3, 2026 is stale; use the March 3, 2027 company-confirmed target.
Primary evidence
FDA target 2027-03-03 — not a guaranteed decision date
Potential outcome market
Will FDA approve zanzalintinib with atezolizumab for previously treated metastatic colorectal cancer under the submitted NDA by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.